106 related articles for article (PubMed ID: 19828471)
21. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
Melotte V; Lentjes MH; van den Bosch SM; Hellebrekers DM; de Hoon JP; Wouters KA; Daenen KL; Partouns-Hendriks IE; Stessels F; Louwagie J; Smits KM; Weijenberg MP; Sanduleanu S; Khalid-de Bakker CA; Oort FA; Meijer GA; Jonkers DM; Herman JG; de Bruïne AP; van Engeland M
J Natl Cancer Inst; 2009 Jul; 101(13):916-27. PubMed ID: 19535783
[TBL] [Abstract][Full Text] [Related]
22. Gene expression patterns distinguish colonoscopically isolated human aberrant crypt foci from normal colonic mucosa.
Glebov OK; Rodriguez LM; Soballe P; DeNobile J; Cliatt J; Nakahara K; Kirsch IR
Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2253-62. PubMed ID: 17119054
[TBL] [Abstract][Full Text] [Related]
23. Development and evaluation of a colorimetric membrane-array method for the detection of circulating tumor cells in the peripheral blood of Taiwanese patients with colorectal cancer.
Wang JY; Yeh CS; Chen YF; Wu CH; Hsieh JS; Huang TJ; Huang SY; Lin SR
Int J Mol Med; 2006 May; 17(5):737-47. PubMed ID: 16596255
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic potential of zinc finger protein-specific autoantibodies and associated linear B-cell epitopes in colorectal cancer.
O'Reilly JA; Fitzgerald J; Fitzgerald S; Kenny D; Kay EW; O'Kennedy R; Kijanka GS
PLoS One; 2015; 10(4):e0123469. PubMed ID: 25875936
[TBL] [Abstract][Full Text] [Related]
25. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A
Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284
[TBL] [Abstract][Full Text] [Related]
26. Applicability of antibody and mRNA expression microarrays for identifying diagnostic and progression markers of early and late stage colorectal cancer.
Spisák S; Galamb B; Sipos F; Galamb O; Wichmann B; Solymosi N; Nemes B; Molnár J; Tulassay Z; Molnár B
Dis Markers; 2010; 28(1):1-14. PubMed ID: 20164542
[TBL] [Abstract][Full Text] [Related]
27. Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients.
Vincenzi B; Zoccoli A; Schiavon G; Iuliani M; Pantano F; Dell'aquila E; Ratta R; Muda AO; Perrone G; Brunelli C; Correale P; Riva E; Russo A; Loupakis F; Falcone A; Santini D; Tonini G
Eur J Cancer; 2013 Apr; 49(6):1501-8. PubMed ID: 23266047
[TBL] [Abstract][Full Text] [Related]
28. Gene expression profiling of colorectal cancer and metastases divides tumours according to their clinicopathological stage.
Koehler A; Bataille F; Schmid C; Ruemmele P; Waldeck A; Blaszyk H; Hartmann A; Hofstaedter F; Dietmaier W
J Pathol; 2004 Sep; 204(1):65-74. PubMed ID: 15307139
[TBL] [Abstract][Full Text] [Related]
29. The humoral immune response to head and neck cancer antigens as defined by the serological analysis of tumor antigens by recombinant cDNA expression cloning.
Vaughan HA; St Clair F; Scanlan MJ; Chen YT; Maraskovsky E; Sizeland A; Old LJ; Cebon J
Cancer Immun; 2004 Jul; 4():5. PubMed ID: 15255672
[TBL] [Abstract][Full Text] [Related]
30. Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients.
Fahmueller YN; Nagel D; Hoffmann RT; Tatsch K; Jakobs T; Stieber P; Holdenrieder S
Int J Cancer; 2013 May; 132(10):2349-58. PubMed ID: 23047645
[TBL] [Abstract][Full Text] [Related]
31. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
Chang SC; Lin JK; Lin TC; Liang WY
Int J Oncol; 2005 Jan; 26(1):65-75. PubMed ID: 15586226
[TBL] [Abstract][Full Text] [Related]
32. CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia.
Yang XF; Wu CJ; McLaughlin S; Chillemi A; Wang KS; Canning C; Alyea EP; Kantoff P; Soiffer RJ; Dranoff G; Ritz J
Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7492-7. PubMed ID: 11416219
[TBL] [Abstract][Full Text] [Related]
33. MAD-CT-2 identified as a novel melanoma cancer-testis antigen using phage immunoblot analysis.
Dubovsky JA; Albertini MR; McNeel DG
J Immunother; 2007 Oct; 30(7):675-83. PubMed ID: 17893560
[TBL] [Abstract][Full Text] [Related]
34. [Expression of tumor-associated antigen LEA and its significance for pathological diagnosis].
Feng H; Song JD
Ai Zheng; 2002 Jun; 21(6):658-62. PubMed ID: 12452070
[TBL] [Abstract][Full Text] [Related]
35. The relation of serum anti-(GalNAc beta) and -para-Forssman disaccharide IgG levels to the progression and histological grading of gastrointestinal cancer.
Smorodin EP; Kurtenkov OA; Sergeyev BL; Chuzmarov VI; Afanasyev VP
Exp Oncol; 2007 Mar; 29(1):61-6. PubMed ID: 17431391
[TBL] [Abstract][Full Text] [Related]
36. Predicting ulcerative colitis-associated colorectal cancer using reverse-transcription polymerase chain reaction analysis.
Watanabe T; Kobunai T; Yamamoto Y; Ikeuchi H; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Kanazawa T; Tanaka T; Yokoyama T; Konishi T; Eshima K; Ajioka Y; Hibi T; Watanabe M; Muto T; Nagawa H
Clin Colorectal Cancer; 2011 Jun; 10(2):134-41. PubMed ID: 21859567
[TBL] [Abstract][Full Text] [Related]
37. Antigens recognized by autologous antibodies of patients with soft tissue sarcoma.
Segal NH; Blachere NE; Shiu HY; Leejee S; Antonescu CR; Lewis JJ; Wolchok JD; Houghton AN
Cancer Immun; 2005 Mar; 5():4. PubMed ID: 15745419
[TBL] [Abstract][Full Text] [Related]
38. Microarray-based identification and RT-PCR test screening for epithelial-specific mRNAs in peripheral blood of patients with colon cancer.
Solmi R; Ugolini G; Rosati G; Zanotti S; Lauriola M; Montroni I; del Governatore M; Caira A; Taffurelli M; Santini D; Coppola D; Guidotti L; Carinci P; Strippoli P
BMC Cancer; 2006 Oct; 6():250. PubMed ID: 17054783
[TBL] [Abstract][Full Text] [Related]
39. Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients.
Toiyama Y; Miki C; Inoue Y; Okugawa Y; Tanaka K; Kusunoki M
Int J Cancer; 2009 Oct; 125(7):1657-62. PubMed ID: 19569242
[TBL] [Abstract][Full Text] [Related]
40. Targeting serum antibody for cancer diagnosis: a focus on colorectal cancer.
Lu H; Goodell V; Disis ML
Expert Opin Ther Targets; 2007 Feb; 11(2):235-44. PubMed ID: 17227237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
